iRadimed (NASDAQ:IRMD) Updates FY 2026 Earnings Guidance

Key Points

• FY2026 guidance: iRadimed provided EPS guidance of $2.060–$2.210 (consensus $2.050) and revenue guidance of $91.0M–$96.0M (consensus $92.4M), and gave Q2 EPS guidance of $0.440–$0.480.
• Dividend increase: The company raised its quarterly dividend to $0.20 (annualized $0.80), implying a ~1.0% yield and a payout ratio of about 45.7%.
• Analyst sentiment: Wall Street’s average rating is "Buy" with a consensus target price of $120, based on one Strong Buy, three Buys and one Hold.

iRadimed (NASDAQ:IRMD - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 2.060-2.210 for the period, compared to the consensus EPS estimate of 2.050. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $92.4 million. iRadimed also updated its Q2 2026 guidance to 0.440-0.480 EPS.

iRadimed Trading Down 0.3%

NASDAQ IRMD opened at $83.44 on Friday. The company has a fifty day simple moving average of $96.69 and a 200 day simple moving average of $93.87. iRadimed has a 12-month low of $50.31 and a 12-month high of $107.90. The company has a market cap of $1.07 billion, a P/E ratio of 47.68 and a beta of 1.11.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The business had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts predict that iRadimed will post 1.94 EPS for the current year.

iRadimed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Monday, February 23rd. This is an increase from iRadimed's previous quarterly dividend of $0.17. iRadimed's payout ratio is 45.71%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IRMD shares. Freedom Capital raised shares of iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. Roth Mkm restated a "buy" rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Lake Street Capital restated a "buy" rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $120.00.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $101.38, for a total value of $506,900.00. Following the transaction, the chief executive officer directly owned 2,242,500 shares of the company's stock, valued at approximately $227,344,650. The trade was a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 48,750 shares of company stock valued at $4,708,950. 36.80% of the stock is owned by insiders.

Hedge Funds Weigh In On iRadimed

A number of hedge funds and other institutional investors have recently made changes to their positions in IRMD. Quarry LP purchased a new position in shares of iRadimed in the 3rd quarter worth about $40,000. Tower Research Capital LLC TRC boosted its holdings in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after buying an additional 495 shares during the last quarter. Virtus Advisers LLC purchased a new position in shares of iRadimed in the 3rd quarter worth about $117,000. Aquatic Capital Management LLC boosted its holdings in shares of iRadimed by 210,400.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider's stock worth $150,000 after buying an additional 2,104 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of iRadimed in the 3rd quarter worth about $164,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.